EGFR and cancer: Instead, we found that combined FGFRi and Akti or PI3K-mTORi exhibited much stronger and superior inhibition of cancer cell growth compared to combined FGFRi and EGFR-TKI across all the erlotinib, gefitinib-, and osimertinib-resistant models.